I spend my life in spreadsheets. If you ask me about a conference, I don’t care about the "thought leadership" fluff; I care about who was in the room, what they were complaining about during the coffee breaks, and whether the sessions actually gave my team actionable intel for Monday morning. After 11 years in commercial ops and managed markets, I’ve learned that most conferences are just expensive networking traps. But 2026 is different. The pressure on pricing and the shift in how we generate evidence has made the conference floor a high-stakes environment.
If you are heading to AMCP, the upcoming THMA forums, or an ACCC meeting this year, stop focusing on the keynote speakers. Start focusing on these four core themes. If you aren't tracking these, your Q4 strategy is already dead in the water.
1. The Death of the "Prescriber-Only" Strategy
For too long, commercial teams have operated like market access is a secondary support function for the sales force. That era is over. The 2026 conference conversations—specifically at AMCP—are dominated by a singular realization: if the payer doesn’t buy it, the prescriber doesn’t matter.
We are seeing a hard pivot. The focus is shifting from "how do we get the rep into the office" to "how do we build an evidence package that prevents the pharmacy benefit manager (PBM) from putting up a roadblock." If your team is still talking about "share of voice" without accounting for the formulary gatekeeper, you are burning cash.
Market Access vs. Prescriber Reach: A Quick Comparison
Feature Old Mindset (Prescriber) 2026 Reality (Access) Primary Goal Increasing NRx/TRx Securing Tier 2/3 placement Key Data Clinical trial endpoints Budget impact models & RWE Decision Maker The Physician The P&T Committee/Health System Admin2. Payer Expectations and the Rise of HTA Pressure
At The Health Management Academy (THMA), the mood isn't just cautious; it's defensive. Payers are under extreme pressure to justify their own spend, and they are passing that heat directly to us. The 2026 conversation has moved past "value-based contracting" into "HTA-style pressure."
They don't want to hear about your drug’s secondary endpoint in a niche population. They want to see the affordability data at scale. They are looking for hard evidence that your therapy doesn't just work, but that it stops the patient from being admitted to a facility two weeks later. If you can’t prove the math, you won’t get the contract.
3. Health System Adoption and Formulary Execution
If you're attending Association of Cancer Care Centers (ACCC) events, listen closely to the health system executives. They are obsessed with institutional adoption. It is no longer enough to get on the national formulary; you have to win the internal battle at the individual hospital or IDN (Integrated Delivery Network) level.
This is where biosimilars are changing the game. Systems are now aggressively managing their own portfolios. They aren't waiting for national guidance; they are creating their own internal protocols for switching and utilization. If your strategy doesn't account for the "local formulary" hurdle, you will find your product gathering dust on the pharmacy shelf regardless of your national status.
4. Digital Tools and the Evidence Gap
I’ve noticed a frustrating trend in how pharma teams try to gather this data. We are relying on digital tools that feel like they were built in 2012. You spend your day crawling through institutional websites to understand formulary updates, only to be blocked by aggressive UI elements like the "Cookie Law Info" plugin that pops up on every site, obscuring the very data you’re trying to scrape or read. It’s a minor annoyance, but it highlights a massive problem: we are bad at digitizing our own evidence generation process.
The successful teams in 2026 are using advanced digital tools to synthesize real-world evidence in real-time. They aren't waiting for the annual congress to see what the competition is doing. They are tracking digital formulary shifts and using automated alerts. Stop manually checking websites. If your ops team isn't automating your competitive intelligence, you’re missing the shift before it happens.
The "Monday Morning" Reality Check
After you pack your bags and leave the conference center, ask yourself this: "What am I actually going to change on Monday?" Most people leave a conference with a bag of swag and a notebook full of platitudes. That is a waste of your company’s travel budget.
Here is your checklist for the plane ride home:
Map the Payer/Provider Disconnect: Did you hear a payer ask for data that your clinical team hasn't prepared yet? Assign that gap to an MSL or medical strategy head immediately. Biosimilar Benchmarking: Did you see a specific health system mention a change in their biosimilar adoption policy? Map that to your account plan for that region. Evidence Utility: Did the RWE you presented actually answer a payer's question, or did it just look good on a slide? Be honest. If it didn't solve a problem, kill the slide. Audit Your Tools: Are your digital intelligence tools actually helping, or are you just getting caught behind the same paywalls and UI pop-ups as everyone else? If you're blocked, get a better subscription.The Bottom Line
Stop overpromising on "networking." If you go to a conference to "meet people," you’re doing it wrong. Go to conferences to find the people who are blocking hub services conference your path or enabling your success. Know exactly who is in the room. If the VP of Pharmacy from a major IDN is speaking, don't just stand in the back. Note exactly what they said about affordability. Use that. Integrate it into your strategy. If you aren't doing that, you're just paying for an expensive lunch.
Market access in 2026 is about speed, precision, and having the courage to kill the projects that don't directly impact the formulary. Keep your notes tight, your focus on the decision-makers, and always ask: does this move the needle on access? If the answer is no, stop talking about it.